-- 生化学工業（東証：4548）は、癒着防止剤「SI-449」が日本で販売承認を取得し、販売パートナーとしてコビディエン・ジャパンを選定したと、水曜日に東京証券取引所に提出した書類で発表した。 「csバリア」として販売されるこの製品は、術後癒着の予防に使用される。発売時期は、保険適用価格が決定した後に決定される予定。
Related Articles
Australia
Rothschild & Co Redburn Adjusts Price Target on Otis Worldwide to $101 From $112, Maintains Buy Rating
Otis Worldwide (OTIS) has an average rating of overweight and mean price target of $93.54, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $78.45, Change: $+0.50, Percent Change: +0.64%
$OTIS
Australia
NICE Says Bell Integration Selects CXone Platform to Support Service Desk Projects
NICE (NICE) said Monday that information technology services and consultancy Bell Integration has selected its CXone platform to back service desk and business development operations.Initial deployment will be in three sites and will support up to 1,000 employees, the company said.Financial details were not provided.NICE shares were up nearly 2% in morning trading.Price: $102.69, Change: $+2.34, Percent Change: +2.33%
$NICE
Australia
BofA Securities Adjusts Price Target on Western Digital to $495 From $415
Western Digital (WDC) has an average rating of overweight and mean price target of $387.27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $402.91, Change: $-1.09, Percent Change: -0.27%
$WDC